Treatment sequencing in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) remains a major unmet clinical need.1 Although somatostatin receptor-positive, well differentiated GEP-NETs ...
Lu]Lu-edotreotide led to statistically significant and clinically meaningful improvements in progression-free survival. Efficacy and harms results support the use of [177Lu]Lu-edotreotide in early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results